Cargando…

Long-Acting Luteinizing Hormone-Releasing Hormone Agonist for Ovarian Hyperstimulation Induced by Tamoxifen for Breast Cancer

Tamoxifen treatment for breast cancer may induce ovarian cysts and supraphysiological levels of serum estrogen. We report successful management with luteinizing hormone-releasing hormone (LHRH) agonist of ovarian hyperstimulation induced by tamoxifen. A 49-year-old woman was operated on for invasive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kojima, Nobue, Yamasaki, Yui, Koh, Houu, Miyashita, Masaru, Morita, Hiroki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827888/ https://www.ncbi.nlm.nih.gov/pubmed/29607235 http://dx.doi.org/10.1155/2018/4931852

Ejemplares similares

Future possibilities in the prevention of breast cancer: Luteinizing hormone-releasing hormone agonists
por: Spicer, Darcy V, et al.
Publicado: (2000)

Variant-beta luteinizing hormone is not associated with poor ovarian response to controlled ovarian hyperstimulation
por: Hanevik, Hans I, et al.
Publicado: (2014)

Progression of Intracranial Meningioma during Luteinizing Hormone-Releasing Hormone Agonist Treatment for Prostate Cancer: Case Report
por: ANDA, Takeo, et al.
Publicado: (2014)

Risk of ovarian hyperstimulation syndrome in women with malignancies undergoing treatment with long-acting gonadotropin-releasing hormone agonist after controlled ovarian hyperstimulation for fertility preservation: a systematic review
por: Ingold, Caroline, et al.
Publicado: (2023)

Association between the luteinizing hormone/chorionic gonadotropin receptor (LHCGR) rs4073366 polymorphism and ovarian hyperstimulation syndrome during controlled ovarian hyperstimulation
por: O’Brien, Travis J, et al.
Publicado: (2013)

Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women
por: Lu, Yen-Shen, et al.
Publicado: (2021)

Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist.
por: Nicholson, R. I., et al.
Publicado: (1979)

Luteinizing hormone-releasing hormone agonists versus orchiectomy in the treatment of prostate cancer: A systematic review
por: Zhang, Xianlu, et al.
Publicado: (2023)

Tamoxifen-induced ovarian hyperstimulation during premenopausal hormonal therapy for breast cancer in Japanese women
por: Yamazaki, Rena, et al.
Publicado: (2015)

Failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer
por: Koh, Yoko, et al.
Publicado: (2020)

The effect of luteinizing hormone changes in GnRH antagonist protocol on the outcome of controlled ovarian hyperstimulation and embryo transfer
por: Zhou, Jing-Shuang, et al.
Publicado: (2023)

Scheduled simple production method of pseudopregnant female mice for embryo transfer using the luteinizing hormone-releasing hormone agonist
por: Sari, Gema Puspa, et al.
Publicado: (2022)

Persistent ascites resolving with gonadotropin-releasing-hormone-agonist 18 months after hospitalization for severe ovarian hyperstimulation syndrome
por: Comba, Cihan, et al.
Publicado: (2013)

Luteinizing Hormone-Releasing Hormone Distribution in the Anterior Hypothalamus of the Female Rats
por: Castañeyra-Ruiz, Leandro, et al.
Publicado: (2013)

The luteinizing hormone beta-subunit exon 3 (Gly102Ser) gene mutation and ovarian responses to controlled ovarian hyperstimulation
por: Davar, Robab, et al.
Publicado: (2014)

Transformation of a prostatic adenocarcinoma into squamous cell carcinoma after luteinizing hormone-releasing hormone (LHRH) agonist and radiotherapy treatment
por: Ichaoui, Hamza, et al.
Publicado: (2019)

Severe ovarian hyperstimulation syndrome and gonadotropin-releasing hormone agonist trigger in patients with hypogonadotropic hypogonadism: A report of two cases
por: Gürbüz, Ali Sami, et al.
Publicado: (2020)

Effects of a luteinizing hormone-releasing hormone agonist on cognitive, sexual, and hormonal functions in patients with prostate cancer: relationship with testicular and adrenal androgen levels
por: Okamoto, Kohei, et al.
Publicado: (2015)

Is It Possible to Prevent Ovarian Hyperstimulation Syndrome by Gonadotropin-Releasing Hormone Agonist Triggering and Modified Luteal Support in Patients With Polycystic Ovarian Morphology?
por: Gurbuz, Ali Sami, et al.
Publicado: (2016)

Utrogestan as an Effective Oral Alternative for Preventing Premature Luteinizing Hormone Surges in Women Undergoing Controlled Ovarian Hyperstimulation for In Vitro Fertilization
por: Zhu, Xiuxian, et al.
Publicado: (2015)

Incidence Rate of Injection-Site Granulomas Resulting from the Administration of Luteinizing Hormone-Releasing Hormone Analogues for the Treatment of Prostatic Cancer
por: Shiota, Masaki, et al.
Publicado: (2007)

Unusual side effect from a luteinizing hormone-releasing hormone agonist, leuprorelin, in the treatment of prostate cancer: a case report
por: Chang, John I-Chiang, et al.
Publicado: (2016)

The use of gonadotropin-releasing hormone antagonist post-ovulation trigger in ovarian hyperstimulation syndrome
por: Chappell, Neil, et al.
Publicado: (2017)

Effect of Exogenous Luteinizing Hormone (LH) Supplementation on Clinical Pregnancy of Patients Receiving Long-Acting Gonadotropin-Releasing Hormone Agonist (GnRHa) Cycles: A Retrospective Cohort Study
por: Huang, Chenyang, et al.
Publicado: (2022)

Topographical localization of the receptors for luteinizing hormone- releasing hormone on the surface of dissociated pituitary cells
Publicado: (1977)

Effects of intravenous administration of neurokinin receptor subtype-selective agonists on gonadotropin-releasing hormone pulse generator activity and luteinizing hormone secretion in goats
por: YAMAMURA, Takashi, et al.
Publicado: (2014)

Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide
por: Shim, Myungsun, et al.
Publicado: (2019)

The enigma of the gonadotropin-releasing hormone pulse frequency governing individual secretion of luteinizing hormone and follicle-stimulating hormone
por: Lambalk, Cornelis B.
Publicado: (2023)

Half-dose, long-acting gonadotropin-releasing hormone agonist (Diphereline) is comparable with daily injections of short-acting gonadotropin-releasing hormone agonist (Suprefact) in IVF/ICSI cycles
por: Tehraninejad, Ensieh Sh., et al.
Publicado: (2010)

Effects of luteinizing hormone-releasing hormone and arginine-vasotocin on the sperm-release response of Günther's Toadlet, Pseudophryne guentheri
por: Silla, Aimee J
Publicado: (2010)

Association of the genetic variants of luteinizing hormone, luteinizing hormone receptor and polycystic ovary syndrome
por: Liu, Nana, et al.
Publicado: (2012)

Characterization of Luteinizing Hormone and Luteinizing Hormone Receptor and Their Indispensable Role in the Ovulatory Process of the Medaka
por: Ogiwara, Katsueki, et al.
Publicado: (2013)

Application of luteinizing hormone-releasing hormone–ferrosoferric oxide nanoparticles in targeted imaging of breast tumors
por: Nian, Di, et al.
Publicado: (2019)

Detection of urinary luteinizing hormone in Japanese black cows after administration of gonadotropin-releasing hormone
por: MIYAZAKI, Tamako, et al.
Publicado: (2021)

Diminished Ovarian Reserve Predisposes to Premature Luteinizing Hormone Surges in Gonadotropin-Releasing Hormone Antagonist Cycles in In vitro Fertilization
por: Kochhar, Puneet Kaur, et al.
Publicado: (2020)

Thyroid Dysfunction Associated with Administration of the Long-Acting Gonadotropin-Releasing Hormone Agonist
por: Han, Eun Jin, et al.
Publicado: (2013)

Luteinizing hormone-releasing hormone analogues in early breast cancer: updated status of ongoing clinical trials.
por: Kaufmann, M.
Publicado: (1998)

Luteinizing hormone-releasing hormone analogues--the rationale for adjuvant use in premenopausal women with early breast cancer.
por: Jonat, W.
Publicado: (1998)

Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma
por: Treszl, Andrea, et al.
Publicado: (2013)

Combination immunotherapy with Survivin and luteinizing hormone-releasing hormone fusion protein in murine breast cancer model
por: Garg, Himani, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_sblp9vrdmu973kas1t4574r7ia